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Ex vivo 18F‑fluoride uptake 
and hydroxyapatite deposition 
in human coronary atherosclerosis
Alastair J. Moss1,2*, Alisia M. Sim3, Philip D. Adamson1,4, Michael A. Seidman5, 
Jack P. M. Andrews1, Mhairi K. Doris1, Anoop S. V. Shah1, Ralph BouHaidar1, 
Carlos J. Alcaide‑Corral1, Michelle C. Williams1, Jonathon A. Leipsic6, Marc R. Dweck1, 
Vicky E. MacRae7, David E. Newby1, Adriana A. S. Tavares1 & Stephanie L. Sellers6
Early microcalcification is a feature of coronary plaques with an increased propensity to rupture and 
to cause acute coronary syndromes. In this ex vivo imaging study of coronary artery specimens, the 
non‑invasive imaging radiotracer, 18F‑fluoride, was highly selective for hydroxyapatite deposition 
in atherosclerotic coronary plaque. Specifically, coronary 18F‑fluoride uptake had a high signal to 
noise ratio compared with surrounding myocardium that makes it feasible to identify coronary 
mineralisation activity. Areas of 18F‑fluoride uptake are associated with osteopontin, an inflammation‑
associated glycophosphoprotein that mediates tissue mineralisation, and Runt‑related transcription 
factor 2, a nuclear protein involved in osteoblastic differentiation. These results suggest that 
18F‑fluoride is a non‑invasive imaging biomarker of active coronary atherosclerotic mineralisation.
Coronary atherosclerosis is an inflammatory disease that results in the formation of intimal plaque with an 
increased propensity to rupture. Microscopic calcification is a key feature of ruptured atherosclerotic plaques and 
the identification of coronary microcalcification is closely linked to coronary thrombotic  events1. However, the 
in vivo mechanisms governing the accumulation of early microscopic calcification within the coronary vascula-
ture are poorly understood. Pre-clinical studies have proposed atherosclerotic inflammation to be an initiator of 
plaque calcification through the extrusion and response to calcifying extracellular  vesicles2,3. Additionally, in vitro 
models of intimal plaque microcalcification have demonstrated that spherical or ellipsoidal micro-calcifying 
vesicles aggregate within plaques and coalesce to form larger plates of  macrocalcification3. Whilst the transition 
from microcalcification to macrocalcification in the vast majority of plaques is thought to confer stability, the 
presence of micro-calcifying vesicles in the tunica intima has the potential to reduce the structural integrity of 
thin-capped fibroatheroma, resulting in plaque  rupture4,5.
Recently, studies have demonstrated that increased 18F-sodium fluoride (18F-fluoride) positron emission 
tomography (PET) uptake is observed in culprit plaques following myocardial infarction and in plaques with 
multiple adverse features in patients with stable  disease1,6–8. 18F-Fluoride preferentially binds to exposed hydroxyl 
groups on the surface of nanocystalline hydroxyapatite. We have previously demonstrated that the signal intensity 
of 18F-fluoride in carotid endarterectomy specimens increases as the size of the calcifications decrease, such that 
18F-fluoride is an imaging biomarker of unbound microscopic  calcification9,10. However, there are important dif-
ferences between carotid and coronary atherosclerotic plaque progression, predominantly attributed to plaque 
composition. Compared with carotid plaques, vulnerable coronary plaques are more prone to rupture owing to 
thinner fibrous caps (< 65 µm versus < 200 µm) and a reduction in smooth muscle cells in the tunica  media11. To 
address these differences in pathophysiology and to fully understand the mechanisms of 18F-fluoride binding 
in coronary atherosclerotic plaque, direct histological examination of coronary artery tissue is  warranted12. In 
this study, we performed an ex vivo histological validation of 18F-fluoride binding to calcium derivatives and 
osteogenic proteins involved in human coronary atherosclerotic calcification.
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Results
Selectivity of 18F‑fluoride for hydroxyapatite. 18F-Fluoride had favourable equilibrium kinetics (Bmax 
9.8 kBq/mL,  Kd 58.14 kBq) for hydroxyapatite with binding equilibrium occurring within 20 min (Fig. 1A). To 
achieve target saturation, 100 kBq of 18F-fluoride was used for subsequent ex vivo experiments. There was high 
selectivity of 18F-fluoride for hydroxyapatite in comparison with other calcium-phosphate derivatives (calcium 
bisphosphate, p < 0.01; calcium pyrophosphate p < 0.001) (Fig. 1B). Very low activity was observed in calcium 
oxalate samples incubated with 18F-fluoride (p < 0.001).
Study population. Between 2016 and 2017, coronary artery samples were obtained at autopsy from 13 
victims of sudden death. The majority were male (n = 10, 76.9%) with a median age of 51 (range 40–71) years. 
Ten deaths (76.9%) were adjudicated as related to ischemic heart disease, one death was attributed to haemo-
Figure 1.  18F-Fluoride binding in ex vivo coronary artery specimens. (A) Total activity of 18F-fluoride (MBq/
mL) following 20 min incubation in hydroxyapatite plotted against dose of 18F-fluoride (kBq) per milligram of 
hydroxyapatite. Scatchard plot of bound/free versus bound 18F-fluoride (inset). (B) Hydroxyapatite and other 
calcium-derived minerals were incubated with 18F-fluoride for 20 min after which unbound supernatant was 
removed and the solid particles were analysed by micro positron emission tomography. Data shown is from at 
least three replicates and shown as the mean ± standard deviation. (C) Micro-computed tomography defined 
regions of myocardium (CT number < 100) from coronary plaque (CT number > 300). Calcification had high 
CT attenuation on micro-computed tomography (CT number > 1000). Quantitative 18F-fluoride positron 
tomography was analysed on hybrid images. (D) Non-specific binding in the surrounding myocardium was 
higher than background activity (median 14.9 [interquartile range 9.6–27.4] versus 0.30 [interquartile range, 
0.09–1.3] kBq/mL respectively, p < 0.0001). Signal in coronary artery segments was tenfold higher (p < 0.0001) 
than myocardium (non-calcified plaque median 158.1 [interquartile range, 121.7–234.8] kBq/mL and calcified 
plaque median 149.8 [interquartile range, 85.3–207.3] kBq/mL). CaPi calcium bisphosphate, CaPyr calcium 
pyrophosphate, CaOx calcium oxalate, HAP hydroxyapatite, WL window level, WW window width. *Indicates 
p < 0.0001
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pericardium from thoracic aortic dissection and two deaths were related to non-cardiac causes (suffocation and 
alcohol toxicity). None of the coronary artery specimens represented culprit or ruptured plaque directly related 
to the sudden death.
18F‑Fluoride co‑localisation with hydroxyapatite. Within tissue sections from the 13 patients, 32 
coronary artery plaques were identified using high-resolution micro-computed tomography. Specifically, the 
morphology and architecture combined with the CT attenuation number of the tissue differentiated coronary 
artery plaques (CT number > 300) from the surrounding myocardium (CT number < 100) (Fig. 1C). 18F-Flu-
oride binding was observed in plaques both with (n = 19) and without (n = 13) areas of macroscopic calcifica-
tion as determined on micro-CT. Total plaque 18F-fluoride binding (median 157.5 [IQR 103.9–216.9] kBq/mL) 
was more than tenfold greater than non-specific binding in the surrounding myocardium (median 14.9 [IQR 
9.6–27.4] kBq/mL, p < 0.0001) and more than 500-fold greater than background regions (median 0.3 [IQR 0.09–
1.3] kBq/mL, p < 0.0001) (Fig. 1D). 18F-Fluoride activity in coronary plaques without macroscopic calcification 
(median 158.1 [IQR 121.7–234.8] kBq/mL) was higher than plaque with macrocalcification (median 149.8 [IQR 
85.3–207.3] kBq/mL; p = 0.0469). In plaques with no observable macrocalcification on micro-computed tomog-
raphy, nanocrystalline calcification was detected using high-intensity 18F-fluoride in focal regions co-localised to 
fibroatheromatous plaques (Fig. 2A–D). In plaques with macrocalcification, high-intensity 18F-fluoride uptake 
was observed in distinct regions remote from larger macrocalcific deposits identified on micro-computed 
tomography (Fig.  2F,G,K,L). Additional low-intensity 18F-fluoride uptake was observed on the exposed sur-
face of macrocalcification (Fig. 2G,L). In the high-intensity regions, 18F-fluoride colocalised with histological 
evidence of microcalcification shown by Von Kossa and Alizarin Red S staining (Fig. 2H,I and M,N respec-
tively). Moreover the microcalcification observed in areas of 18F-fluoride binding was specifically classified as 
hydroxyapatite using a highly selective immunofluorescence probe, fluorescein-bisphosphonate (Fig. 2E,J,O).
Raman spectroscopy and 18F‑fluoride intensity. Raman spectroscopy imaging of selected regions 
with high and low-intensity 18F-fluoride binding was performed in eight samples (Fig. 3A–L). The characteristic 
cell Raman signal was observed in all these samples at 1004 cm−1 corresponding to phenylalanine. In a control 
Figure 2.  18F-Fluoride, coronary microcalcification and hydroxyapatite deposition. Coronary artery 
specimens had no macrocalcification detected by micro-computed tomography (A) and macrocalcification 
in a circumferential pattern (F) or large calcified nodules (K). High-intensity 18F-Fluoride binding occurred 
in regions remote from these regions of macrocalcification observed on micro-computed tomography in the 
intimal layer of fibroatheromatous plaques (B,G,L). Low-intensity 18F-fluoride activity was noted on the exposed 
surface of macrocalcified deposits (G,L). Magnified histological analysis (white dotted region) demonstrated 
co-localisation with evidence of tissue mineralisation using Von Kossa staining (C,H,M), microcalcification 
using Alizarin Red S staining (D,I,N) and hydroxyapatite deposition using a hydroxyapatite-specific 
bisphosphonate probe (blue dotted region), fluorescein-bisphosphonate [green] (E,J,O). WL window level, WW 
window width.
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sample with no 18F-fluoride signal or calcification on Alizarin Red S staining (Fig. 3A–C), no Raman signal was 
observed in the range between 940 and 1000 cm−1 (Fig. 3D). Samples containing microcalcification identified 
by high-intensity 18F-fluoride (157  kBq/mL) (Fig.  3E–G) had a Raman signal at 963  cm−1 corresponding to 
hydroxyapatite (Fig. 3H). In macrocalcified specimens with low-intensity 18F-fluoride (30 kBq/mL) (Fig. 3I–
K), Raman signal with an asymmetrical v1 stretching band appeared at 973 cm−1 corresponding to whitlockite 
(Fig. 3L). As there was an asymmetrical peak to signal in these macrocalcified specimens, further analysis of the 
area under the whitlockite peak revealed two overlapping peaks attributable to hydroxyapatite and whitlockite 
at a ratio of 30:70.
18F‑Fluoride co‑localisation with markers of osteogenic activity in coronary arteries. Detailed 
analysis of coronary artery specimens revealed that 18F-fluoride binding was predominantly observed within 
the tunica intima in areas of plaque formation (Fig. 4A). Little or no binding was observed in the tunica media. 
In coronary atherosclerotic plaques without macrocalcification, there was no intense staining for alkaline phos-
phatase (weakly positive) despite high-intensity 18F-fluoride activity. However, these regions of high-intensity 
18F-fluoride co-localised with the increased expression of osteopontin (Fig. 4A). Osteopontin deposition was not 
observed in regions without high 18F-fluoride activity (Fig. 4B). Osteopontin-positive plaques had higher 18F-flu-
oride activity compared to those without (mean 145 versus 94.5 kBq/mL respectively: difference in means 50.5 
[95% confidence interval 28.1–72.9] kBq/mL, p < 0.0001) (Fig. 4C). Similarly, Runt-related transcription factor 
2 (Runx-2) positive plaques had higher 18F-fluoride activity compared to those without (mean 139.8 versus 
102.6 kBq/mL respectively; difference in means 37.2 [95% confidence interval 12.6–61.8] kBq/mL, p = 0.0043) 
(Fig. 4D). Staining for transforming growth factor beta 1 and caspase 3 was evident in these plaques, particularly 
in regions of macrocalcification. However, 18F-fluoride activity did not correlate with increased staining for 
transforming growth factor beta 1 (TGFβ1, p = 0.1042), wingless/integrated 3a (WNT3A, p = 0.8732) or caspase 
3 (p = 0.5476).
Figure 3.  18F-Fluoride with Raman spectroscopy for hydroxyapatite and whitelockite. Coronary artery 
specimens with high-intensity 18F-fluoride binding and low-intensity 18F-fluoride binding underwent Raman 
spectroscopy analysis to differentiate mineral composition (n = 8). Non-macrocalcified specimens with 
low-intensity 18F-fluoride intensity (control, n = 1) had a single spectra peak at 1004 cm−1 corresponding to 
phenylalanine (A–D). Focal regions with no macrocalcification and high-intensity 18F-fluoride intensity (n = 3) 
had a Raman spectra peak at 963 cm−1, hydroxyapatite (E–H). Macrocalcified regions with low-intensity 
18F-fluoride intensity had a Raman spectra peaks at 975 cm−1, whitlockite (I–L). Raman Shift: Hydroxyapatite, 
963 cm−1, Whitlockite, 973 cm−1, Phenylalanine, 1004 cm−1. WL window level, WW window width.
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Discussion
In this ex vivo imaging study of coronary atherosclerosis, we have demonstrated for the first time that 18F-fluoride 
is a selective marker of intimal hydroxyapatite deposition in human coronary atherosclerotic plaques. Similar 
to other disease states it preferentially binds in areas of coronary microcalcification rather than macrocalcifica-
tion. 18F-Fluoride has a high affinity for hydroxyapatite, which has a higher surface area for binding in regions 
of microcalcification compared with larger macrocalcified deposits. Importantly, high 18F-fluoride signal co-
localises with the distribution of osteopontin and Runx-2, established markers of early calcification activity and 
adverse plaque formation. This histological validation supports the use of 18F-fluoride positron emission tomog-
raphy as a marker of developing microcalcification and plaque activity in patients with coronary artery disease.
Whilst there has been histological confirmation of 18F-fluoride binding in carotid atheroma, studies dem-
onstrating increased 18F-fluoride activity in the coronary  arteries1,7 have been called into question due to the 
limited spatial resolution of clinical positron emission tomography, with some investigators questioning whether 
18F-fluoride binding actually occurs in coronary  arteries14. In this regard, the confirmation of high-intensity 
18F-fluoride binding in the intimal layer of coronary plaques compared to background and adjacent myocardium 
is of considerable importance. We have also confirmed that 18F-fluoride binding occurs in plaques both with 
Figure 4.  18F-Fluoride and transcription factors associated with atherosclerotic mineralisation. 
Fibroatheromatous plaques with high 18F-fluoride activity had an abundance of microcalcification (Alizarin 
Red S) (A). The distribution of the biomineralisation glycophosphoprotein osteopontin and the nuclear factor 
of osteoblastic differentiation Runt-related transcription factor 2 colocalised with microcalcification in the 
intimal layer (A). In regions without high-intensity 18F-fluoride activity no deposition of osteopontin or Runt-
related transcription factor 2 was seen (B). High-intensity 18F-fluoride activity was associated with markers 
of inflammatory mediated mineralisation (Osteopontin: positive 145.0 kBq/mL versus negative 94.5 kBq/mL, 
difference in means 50.5 [95% confidence interval 28.1–72.9] kBq/mL, p < 0.0001 (C); Runt-related transcription 
factor 2: positive 139.8 kBq/mL versus negative 102.6 kBq/mL, difference in means 37.2 [95% confidence 
interval 12.6–61.8] kBq/mL, p = 0.0043) (D). OPN, Osteopontin, RUNX-2, Runt-related transcription factor 2.
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and without macroscopic calcium observed on CT, and that binding appears to occur preferentially in regions 
of developing microcalcification. These findings are consistent with previous observations in coronary artery 
disease as well the data in carotid atheroma and other cardiovascular disease  states9,10,15–17.
Of particular interest is the potential for 18F-fluoride to discriminate hydroxyapatite deposition above other 
calcium derivatives in regions of active  mineralisation18. Of the many calcium derivatives, nanocrystalline 
hydroxyapatite is the central component of microcalcification in atherosclerotic coronary  plaques18. We have 
here confirmed the preferential binding of 18F-fluoride for microcalcification and for hydroxyapatite based upon 
the binding of a specific optical probe and Raman spectroscopy. At later stages in the calcification process, 
other calcium derivatives, such as whitlockite, become more abundant in calcified vascular tissue, particularly 
within large vessel atherosclerosis where there is often a high whitlockite to hydroxyapatite  ratio19. The phase 
transformation of hydroxyapatite to whitlockite may occur in the hypoxic or acidic conditions within necrotic 
cores where magnesium ions are incorporated onto the surface and prevent further growth of hydroxyapatite 
 crystals20. Traditionally surface area effects have been used to explain the preferential binding of 18F-fluoride for 
microcalcification. However, the specificity of 18F-fluoride for hydroxyapatite provides an additional explana-
tion for why high 18F-fluoride activity is not observed in areas macrocalcification and why it provides different 
information to  CT9.
We also observed a close relationship between the coronary 18F-fluoride signal and both osteopontin and 
Runx-2 expression, established markers of early calcification activity and adverse coronary plaque. High concen-
trations of osteopontin accumulate in coronary atheroma exposed to hypoxia and endothelial  injury21. Of note, 
inflammatory signalling within metabolically active coronary plaques stimulates macrophage-derived foam cells 
to express high levels of  osteopontin22. In comparison, low levels of osteopontin mRNA are found in vascular 
smooth muscle cells often regarded as the cell type responsible for initiating plaque  calcification23. Importantly, 
from a clinical perspective, high plasma osteopontin levels are associated with adverse clinical events in patients 
with both stable and unstable coronary artery  disease24,25. Combined with high-sensitivity C reactive protein, 
osteopontin had a two-fold increased risk of recurrent myocardial infarction in patients presenting with ST 
elevation myocardial  infarction25. The role of osteopontin in mediating plaque activity is noted by the beneficial 
effect of statins in reducing osteopontin levels and thereby reduce the risk of plaque  rupture26. The relationship 
between 18F-fluoride uptake and osteopontin therefore supports its role as a marker of early calcification activity 
and adverse plaque formation. However, ultimately data are required to investigate whether 18F-fluoride pre-
dicts future myocardial infarction and therefore might provide important clinical information. In this regard, 
to determine whether coronary 18F-fluoride has clinical utility, prognostic observation studies in patients with 
recent myocardial infarction are ongoing (NCT02278211).
Co-localisation of 18F-fluoride uptake to specific coronary atheromatous plaques presents some challenges 
when conducting clinical positron emission tomography and computed tomography coronary angiography in 
patients with coronary artery disease. The small calibre of the coronary arteries leads to partial volume averag-
ing, and the near continuous motion from cardiac and respiratory cycles can limit signal localisation to specific 
regions of the coronary circulation. Some of these issues can be improved by use of beta-blockade, motion 
correction and advanced image analysis  techniques27. The present study is therefore important to reaffirm that 
18F-fluoride is binding to individual advanced human coronary atheromatous plaques as well as identify the 
components to which it binds. The emerging clinical application of 18F-fluoride positron emission tomography 
and computed tomography coronary angiography is able to provide clinicians with a tool to monitor disease 
activity and identify individuals at increased risk of future coronary  events28. Since the probability of an indi-
vidual ruptured plaque causing an acute coronary event is low, 18F-fluoride positron emission tomography and 
computed tomography coronary angiography is best utilised to detect overall coronary atherosclerotic disease 
activity in vulnerable patients rather than localising specifically to a single vulnerable  plaque29.
There are some limitations to this study. Legislation regarding the regulation of tissue in victims of sudden 
death meant that only left main and proximal left anterior descending coronary artery specimens could be 
obtained for detailed research analysis. These specimens did not include sections of culprit coronary plaque 
rupture with thrombus formation and therefore extrapolation of these findings to ruptured atherosclerotic 
plaques cannot be made. Additionally, specimen preparation and handling between different imaging modalities 
may have resulted in alterations in the orientation and alignment of the datasets. Ante-mortem demographics 
regarding risk factors such as diabetes mellitus and renal disease which influence atherosclerotic calcification 
were unavailable. However, the majority of cases in this study were adjudicated by a forensic pathologist who 
determined a cause of death attributed to ischemic heart disease independent from the study investigators. 
This provides further evidence of the high prevalence of 18F-fluoride binding in coronary arteries in a high-risk 
cohort. Although the significance of the high frequency of sudden cardiac death (77%) in this study population 
is uncertain, further studies exploring the utility of coronary 18F-fluoride imaging in victims of sudden death 
are worth pursuing.
Conclusions
In this ex vivo study of coronary atherosclerotic plaques, 18F-fluoride binding was highly selective for unbound 
hydroxyapatite deposition. High 18F-fluoride intensity was associated with intimal microcalcification in regions 
of osteopontin and Runx-2 expression. This study provides further evidence to support the use of 18F-fluoride 
positron emission tomography as a marker of plaque vulnerability in patients with coronary artery disease.
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Methods
Saturation binding assays to quantify 18F‑fluoride binding kinetics and selectivity to 
hydroxyapatite. Saturation radioligand binding experiments to determine the number of binding sites 
(Bmax) and the dissociation constant  (Kd) of 18F-fluoride were undertaken using nanocrystalline hydroxyapa-
tite phantoms prior to performing ex  vivo imaging. Five-milligram vials of hydroxyapatite were incubated 
with 18F-fluoride (110, 230, 470 or 700 kBq/mL) for 20 min. The supernatant fraction was then removed and 
hydroxyapatite was twice washed in 10 mL 0.9% sodium chloride for 5 min to remove unbound 18F-fluoride. 
Hydroxyapatite phantoms were scanned using high-resolution micro-PET (1:5 coincidence mode) and com-
puted tomography (CT) with semi-circular full trajectory, maximum field of view, 480 projections, 50  kVp, 
300  ms and 1:4 binning (Mediso nanoScan PET/CT, Mediso Medical Imaging Systems, Hungary) and total 
activity counts over 30 min were measured. PET data were reconstructed using Mediso’s iterative Tera-Tomo 3D 
reconstruction algorithm using 4 iterations, 6 subsets, full detector model, normal regularization, spike filter on, 
voxel size 0–6 mm and 400–600 keV energy window. Micro-PET-CT images were analysed on an OsiriX work-
station (OsiriX version 7.5.1, 64-bit, OsiriX Imaging Software, Geneva, Switzerland). Regions of interest were 
drawn around contours of phantoms on the CT and mapped to corresponding fused 18F-fluoride positron emis-
sion tomographic images. Total binding activity curves and Scatchard plots were generated to calculate Bmax 
and  Kd of 18F-fluoride for subsequent ex vivo experiments. To ensure saturation of binding sites, 2 × Kd was used 
to evaluate the selectivity of 18F-fluoride for hydroxyapatite compared with phantoms of calcium phosphate, 
calcium oxalate and calcium pyrophosphate using the method described above.
Cadaveric coronary arteries and ex vivo 18F‑fluoride micro‑positron emission tomography 
computed tomography. Atherosclerotic sections of left coronary arteries were obtained from victims of 
sudden death (both cardiac and non-cardiac) with ethical approval and informed relative authorisation from the 
next of kin (National Health Service South East Scotland Research Ethics Committee 14/SS/1090). Tissue was 
independently obtained at time of autopsy by the performing pathologist (RB). Legislation regarding the regula-
tion of tissue in victims of sudden death meant that only left main and proximal left anterior descending coro-
nary artery specimens could be obtained for detailed research analysis. These were obtained with the surround-
ing myocardium and did not necessarily include the specific culprit plaque for patients who had suffered acute 
myocardial infarction. Tissue was immediately fresh frozen at − 80 °C. Thawed non-decalcified coronary artery 
specimens were incubated for 20 min in 18F-fluoride 100 kBq/mL solution (10.5 MBq 18F-fluoride in 99.5 mL 
0.9% sodium chloride). Specimens were twice washed in 10 mL 0.9% sodium chloride for 5 min to remove 
unbound 18F-fluoride. Specimens were scanned using the microPET-CT protocol described above. Regions 
of interest were drawn in background regions, myocardium, non-calcified and calcified segments in coronary 
artery plaques using micro-CT images and the maximum 18F-fluoride activity in each region was recorded on 
co-registered micro-PET images. Maximum activity recorded in a region equal to or above 100 kBq/mL was 
defined as high-intensity 18F-fluoride (> 5 × myocardium activity), whereas values with a maximum activity of 
less than 100 kBq/mL was defined as low-intensity. After whole specimen imaging, the coronary arteries were 
fixed in 10% (w/v) neutral buffered formalin.
Sample preparation and histological examination. Formalin-fixed coronary arteries were sectioned 
into 2–4 mm slices by a vascular biology/pathology lab (MS, SS). The resulting slices were embedded in paraffin 
which provided 1–8 tissue cross-sections analysed per sample depending on the size of tissue initially isolated. 
Paraffin sections (4 µm) were used for histology and immunohistochemistry as described below. In all cases, 
images were generated using an Aperio Slide Scanner using ImageScope software (Leica Biosystems, Germany). 
Histological examination was performed using haematoxylin and eosin staining for overall pathology, followed 
by Movat’s pentachrome and trichome staining to differentiate fibrosis and elastic fibres. Von Kossa and Alizarin 
Red S staining were used to assess for the presence of calcification.
Fluorescein‑bisphosphonate immunofluorescence of cadaveric coronary arteries. To deter-
mine whether the binding of 18F-fluoride in regions of Von Kossa and Alizarin Red S was specific for hydroxyapa-
tite deposition, categorisation of these regions using a fluorescein-bisphosphonate probe was undertaken. 
Fluorescein-bisphosphonate is a highly sensitive and specific probe for identifying regions of microcrystalline 
hydroxyapatite. Incubation and binding in tissue has previously been described in  detail13. Briefly, sections were 
de-waxed in xylene and incubated with fluorescein-bisphosphonate (1 µM) for 2 h, washed in water (2 ×) fol-
lowed by incubation with 2% Alizarin Red S (250 µL) for 5 min. Sections were washed in water (3 ×) and sub-
sequently incubated with 4′,6-diamidino-2-phenylindole (500 nM) for 5 min. Sections were washed with water 
(1 ×) and then mounted using ProLong Gold Antifade. Fluorescence signal was detected under a Leica DMRB 
fluorescence microscope.
Raman spectroscopy. Coronary artery specimens were embedded in paraffin wax, sectioned and sub-
sequently placed on calcium fluoride slides. Once dried, the slides were placed in xylene for 15 min followed 
by dehydration in ethanol. As soon as they were dehydrated, the sections were ready for imaging and did not 
require additional processing. Alizarin Red S staining was used to discriminate regions of calcification. Sec-
tions from tissue presenting no calcification, calcification with low fluoride intensity (< 100 kBq/mL), and no 
calcification with high fluoride intensity (≥ 100 kBq/mL) were selected in order to address whether there were 
any differences in the apatite crystal or molecular substitution in the structure. Raman imaging was carried out 
using an InVia Renishaw Microscope with a 785 nm laser excitation source which was used to excite the sample 
through a 50, N.A. 0.75 objective. The total data acquisition was performed during 60 s for spectra with a 100% 
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laser power using the WiRE software (Renishaw, Gloucestershire, United Kingdom). All of the spectra acquired 
were background subtracted using a background correction algorithm.
Immunohistochemical categorisation of osteogenic markers. Immunohistochemistry was com-
pleted using osteopontin (OPN) (Sigma-Aldrich Catalog No: O7264, 1:100 dilution), Runt-related transcription 
factor 2 (Runx-2) (Abcam Catalog No: Ab76956, 1:50 dilution), transforming growth factor beta 1 (TGFβ1) 
(Abcam Catalog No: Ab64715, 1:25 dilution), wingless/integrated 3a (Wnt3A) (Abcam Catalog No: Ab28472, 
1:200 dilution) and Caspase 3 (Cell Signalling No: 9664, 1:100 dilution). Staining was performed via automated 
staining with a Leica Bond Rx system using Bond Epitope Retrieval Solution 1 (pH = 6, Catalog No: AR9961) 
and Bond Polymer Refine Red Detection (Catalog No: DS9390). The omission of the primary antibody served 
as negative controls. Blinded qualitative categorisation of nuclear staining intensity was performed by a patholo-
gist using a 4-point classification: 0, no notable staining, 1, < 20% of plaque or relevant cells are weakly positive, 
2, < 50% of plaque or some relevant cells are strongly positively, 3, 50–100% of plaque or all relevant cells are 
strongly positive. For comparison of immunohistochemical analysis with 18F-fluoride activity, plaques with a 
classification 3 were defined as ‘positive’ and classification < 3 was defined as ‘negative’ for osteopontin, runt-
related transcription factor 2, transforming growth factor beta 1 and wingless/integrated 3a. Plaques with clas-
sification 2 were defined as ‘positive’ and classification < 2 were defined as ‘negative’ for Caspase 3.
Statistical analysis. Categorical variables are reported as number (%) and continuous variables as 
mean ± standard deviation for parametric or median and interquartile range for non-parametric data. Normal-
ity was tested for using the D’Agostino and Pearson test. Continuous unpaired variables were compared using 
Student’s t test with Welch’s correction when two samples had unequal variances and/or unequal sample sizes. 
Non-parametric data was compared between two categories using Mann–Whitney U test or using Kruskal–Wal-
lis test for multiple categories. Statistical analysis was undertaken using PRISM for OS X, version 8.1.1 (Graph-
Pad Software, San Diego, California, USA). Statistical significance was considered as a two-sided p value < 0.05.
Ethical approval. Tissue samples were obtained at autopsy with written informed relative authorisation 
from the next of kin. Ethical approval was granted by National Health Service Research Ethics Committee South 
East Scotland (14/SS/1090). The retention, storage and use of tissue sections were compliant with the United 
Kingdom Human Tissue Act of 2004 and in accordance with the relevant guidelines and regulations approved 
by National Health Service Research Ethics Committee South East Scotland (14/SS/1090).
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